ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy
- 15 October 2020
- journal article
- letter
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (8), 1184-1187
- https://doi.org/10.1164/rccm.202002-0286le
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2020
- 118: RESOURCE UTILIZATION IN THE ICU IN CRITICALLY ILL PATIENTS FOLLOWING CAR T CELL THERAPYCritical Care Medicine, 2020
- Critical Care Management of Chimeric Antigen Receptor T Cell–related Toxicity. Be Aware and PreparedAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2018
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceBlood, 2018
- National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and PaymentThe New England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014